First Light Diagnostics Forms World-Class International Clinical Advisory Board

CHELMSFORD, Mass., February 21, 2019 (Newswire.com) - First Light Diagnostics, Inc., a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the establishment of a Clinical Advisory Board (CAB). The board is a growing list of members asked to participate based on world-renowned expertise in the fields of microbiology, epidemiology, infection detection and prevention.

First Light's CAB is tasked with providing expert guidance as the business develops and commercializes their novel Multipath™ platform for the detection of infections and infectious agents and the determination of effective, targeted, antibiotic treatment.

"We are pleased to announce the formation of our Clinical Advisory Board," said David Macdonald, CEO of First Light Diagnostics. "We endeavor to build an advisory team of leading experts in their fields that can bring a broad range of experience and real-world expertise to help guide the evolution of our MultiPath technology."

In addition to the Clinical Advisory Board, First Light Diagnostics has assembled industry experts across key business disciplines including research and development, commercialization, sales and marketing, and regulatory affairs. This group is tasked with providing the commercial foundation for First Light Diagnostics as it moves into the next phase of its evolution.

The following industry experts are the current members of the First Light Diagnostics Clinical Advisory Board:

Dr. Ciaran P. Kelly, who serves as the Chief of the Herrman L. Blumgart Internal Medicine Firm and as Director of Gastroenterology Training and Medical Director of the Celiac Center at Beth Israel Deaconess Medical Center, Boston, Massachusetts, as well as participating in several clinical advisory boards.

Dr. Mark Wilcox, who serves as a Consultant Microbiologist, Head & Professor of Medical and Academic Lead of Pathology/Clinical Director of Pathology, at the Leeds Teaching Hospitals (LTHT) and is the lead on Clostridium difficile for Public Health England in the UK.

Dr. Dale N. Gerding. who is a past president of the Society for Healthcare Epidemiology of America and past chair of the antibiotic resistance committee of SHEA as well as a fellow of the Infectious Diseases Society of America (IDSA) and is co-chair of the guideline for Infection of IDSA and SHEA.

Dr. James Kirby, who is the Medical Director of Clinical Microbiology at Beth Israel Deaconess Medical Center and an Associate Professor of Pathology at Harvard Medical School. He is Board Certified in Clinical Pathology and is a Diplomat of the American Board of Medical Microbiology.

To learn more about the First Light Diagnostics Clinical Advisory Board and additional advisors, visit the Advisory Board Page.

About First Light Diagnostics

First Light Diagnostics, Inc., is developing and preparing to commercialize, innovative diagnostic products for rapid, sensitive and cost-saving detection of life-threatening infections, and combating the spread of antibiotic resistance. Don Straus is the company's Founder and primary inventor of the company's core scientific technology. Based on its proprietary MultiPath™ detection technology, First Light's products combine the clinical performance of the most advanced commercial laboratory tests with speed, cost-effectiveness, and ease-of-use. The tests rapidly detect infections, identify infectious agents, and determine effective targeted antibiotic therapy. This will improve patient outcomes, reduce healthcare costs, and prevent inappropriate use of powerful antibiotics. To learn more, please visit: www.firstlightdx.com

David Macdonald
President and CEO
First Light Diagnostics
[email protected]
Mobile: (858) 997-9641

Source: First Light Diagnostics